McNeill Jonathan
- SEC CIK
- 0001824673
In the past year, 2 open-market sale filings worth $446.9K and no purchases.
Current role at each company
- CBIO Crescent Biopharma, Inc.President and COOas of Sep 18, 2026
- DYN Dyne Therapeutics, Inc.Chief Business Officeras of Aug 20, 2024
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $446.9K
- 2 filings
- Net
- −$446.9K
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists McNeill Jonathan as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
CBIO Crescent Biopharma, Inc.
President and COO2 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 23, 2026 (view filing) | Jun 22 | 1 day | McNeill JonathanPresident and COO | SSale | −20.5K | $17.99 | −$369.7K | −12.9%139.2K after | 10b5-1 |
| Sep 18, 2026 (view filing)4:01 PM ET | Sep 16-18 | 2 days | McNeill JonathanPresident and COO | SSale | −4.57K | $16.90 | −$77.2K | −3.3%134.6K after | 2 lots10b5-1 |
DYN Dyne Therapeutics, Inc.
Chief Business Officer18 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 22, 2021 (view filing) | Sep 20-21 | 2 days | McNeill JonathanSee Remarks | SSale | −1.27K | $15.90 | −$20.3K | −3.5%35.6K after | 2 lots |
| Mar 14, 2022 (view filing) | Mar 11 | 3 days | McNeill JonathanSee Remarks | SSale | −481 | $8.73 | −$4.20K | −0.8%60.5K after | |
| Dec 13, 2022 (view filing) | Dec 12 | 1 day | McNeill JonathanSee Remarks | SSale | −472 | $10.87 | −$5.13K | −0.5%97.8K after | |
| Jan 11, 2023 (view filing) | Jan 9 | 2 days | McNeill JonathanSee Remarks | SSale | −30.1K | $11.57 | −$348.8K | −30.8%67.6K after | |
| Jan 23, 2023 (view filing) | Jan 18 | 5 daysLate | McNeill JonathanSee Remarks | SSale | −10.0K | $14.03 | −$140.3K | −12.9%67.6K after | |
| Mar 15, 2023 (view filing) | Mar 13-14 | 2 days | McNeill JonathanSee Remarks | SSale | −2.21K | $13.18 | −$29.1K | −3.3%65.4K after | 2 lots |
| Jun 14, 2023 (view filing) | Jun 12-13 | 2 days | McNeill JonathanSee Remarks | SSale | −2.26K | $12.68 | −$28.6K | −3.5%63.1K after | 2 lots10b5-1 |
| Sep 13, 2023 (view filing) | Sep 12 | 1 day | McNeill JonathanChief Business Officer | SSale | −1.27K | $10.41 | −$13.2K | −2.0%61.9K after | 10b5-1 |
| Sep 20, 2023 (view filing) | Sep 18 | 2 days | McNeill JonathanChief Business Officer | SSale | −1.26K | $9.41 | −$11.9K | −2.0%60.6K after | |
| Dec 12, 2023 (view filing) | Dec 11 | 1 day | McNeill JonathanChief Business Officer | SSale | −1.25K | $10.72 | −$13.3K | −0.8%155.5K after |